Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Merck
Chinese Patent Office
Mallinckrodt
Farmers Insurance
Express Scripts
Teva
Chubb
Johnson and Johnson
Fish and Richardson

Generated: February 21, 2018

DrugPatentWatch Database Preview

Aralez Pharms Company Profile

« Back to Dashboard

Summary for Aralez Pharms
International Patents:194
US Patents:10
Tradenames:4
Ingredients:4
NDAs:4

Drugs and US Patents for Aralez Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aralez Pharms Inc FIBRICOR fenofibric acid TABLET;ORAL 022418-001 Aug 14, 2009 RX Yes No 7,569,612 ➤ Sign Up ➤ Sign Up
Aralez Pharms Inc FIBRICOR fenofibric acid TABLET;ORAL 022418-002 Aug 14, 2009 RX Yes Yes 7,741,374 ➤ Sign Up ➤ Sign Up
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No 9,539,214 ➤ Sign Up ➤ Sign Up
Aralez Pharms ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes 7,235,567 ➤ Sign Up Y Y ➤ Sign Up
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No 9,364,439 ➤ Sign Up Y ➤ Sign Up
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-002 Sep 14, 2016 RX Yes Yes 8,206,741 ➤ Sign Up Y ➤ Sign Up
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-002 Sep 14, 2016 RX Yes Yes 6,926,907 ➤ Sign Up Y ➤ Sign Up
Aralez Pharms Inc FIBRICOR fenofibric acid TABLET;ORAL 022418-002 Aug 14, 2009 RX Yes Yes 7,915,247 ➤ Sign Up ➤ Sign Up
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No 8,206,741 ➤ Sign Up Y ➤ Sign Up
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Aralez Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-003 Jan 10, 1992 5,246,714*PED ➤ Sign Up
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-002 Jan 10, 1992 3,998,790 ➤ Sign Up
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-002 Jan 10, 1992 5,081,154*PED ➤ Sign Up
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-004 Feb 5, 2001 4,927,640*PED ➤ Sign Up
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-004 Feb 5, 2001 5,081,154*PED ➤ Sign Up
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-001 Jan 10, 1992 4,957,745*PED ➤ Sign Up
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-003 Jan 10, 1992 4,927,640*PED ➤ Sign Up
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-002 Jan 10, 1992 5,246,714*PED ➤ Sign Up
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-002 Jan 10, 1992 3,876,802 ➤ Sign Up
Aralez Pharms TOPROL-XL metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 019962-004 Feb 5, 2001 5,246,714*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ARALEZ PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 81 mg/40 mg ➤ Subscribe 10/14/2016

Non-Orange Book US Patents for Aralez Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,488,742 Thrombin receptor antagonists ➤ Sign Up
8,557,285 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
8,865,190 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,393,208 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Sign Up
6,894,065 Thrombin receptor antagonists ➤ Sign Up
9,161,920 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,220,698 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Sign Up
9,707,181 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,345,695 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,198,888 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Aralez Pharms Drugs

Country Document Number Estimated Expiration
European Patent Office 2301930 ➤ Sign Up
Germany 60129698 ➤ Sign Up
Austria 455774 ➤ Sign Up
Cyprus 1111363 ➤ Sign Up
Norway 20035275 ➤ Sign Up
Norway 2015016 ➤ Sign Up
Israel 153308 ➤ Sign Up
Slovakia 287026 ➤ Sign Up
Norway 333836 ➤ Sign Up
Germany 60317493 ➤ Sign Up
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Aralez Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0746 Netherlands ➤ Sign Up PRODUCT NAME: VORAPAXAR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER VORAPAXARSULFAAT; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150121
858 Luxembourg ➤ Sign Up 91858, EXPIRES: 20251105
500036 Hungary ➤ Sign Up PRODUCT NAME: VORAPAXAR; REGISTRATION NO/DATE: EU/1/14/976 20150119
00481 Netherlands ➤ Sign Up PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
2012 00036 Denmark ➤ Sign Up
11/016 Ireland ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
2015 00037 Denmark ➤ Sign Up PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119
90013-1 Sweden ➤ Sign Up PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
2015027 Lithuania ➤ Sign Up PRODUCT NAME: VORAPAXARUM; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119
1411900/01 Switzerland ➤ Sign Up PRODUCT NAME: ESOMEPRAZOL + NAPROXEN; REGISTRATION NO/DATE: SWISSMEDIC 61330 06.05.2011
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
AstraZeneca
Merck
Moodys
Harvard Business School
Farmers Insurance
US Department of Justice
McKesson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot